| Literature DB >> 30670033 |
Sebastian Rauschert1, Antonio Gázquez1,2, Olaf Uhl1, Franca F Kirchberg1, Hans Demmelmair1, María Ruíz-Palacios2, María T Prieto-Sánchez3, José E Blanco-Carnero3, Anibal Nieto3, Elvira Larqué2, Berthold Koletzko4.
Abstract
OBJECTIVE: The aim of this study was to analyse the differences in the phospholipid composition of very low density (VLDL), low density (LDL) and high density lipoprotein (HDL) monolayers in pregnant lean and obese women.Entities:
Keywords: Lipidomics; Lipoproteins; Obesity; Phosphatidylcholine; Pregnancy; Sphingolipids; Sphingomyelin
Mesh:
Substances:
Year: 2019 PMID: 30670033 PMCID: PMC6343318 DOI: 10.1186/s12944-019-0957-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Characteristics of pregnant women
| Control ( | Obese ( |
| |
|---|---|---|---|
| Age (years) | 33.80 ± 1.87 | 34.50 ± 2.31 | 0.807 |
| Pregestational BMI (kg/m2) | 22.51 ± 0.50 | 32.22 ± 0.92 | < 0.001 |
| BMI at delivery (kg/m2) | 28.22 ± 0.57 | 35.63 ± 1.18 | < 0.001 |
| Glucose (mg/dl) | 59.80 ± 2.48 | 62.10 ± 6.271 | 0.377 |
| Insulin (UI) | 9.47 ± 1.50 | 14.73 ± 2.68 | 0.090 |
| TG (mmol/L) | 1.94 ± 0.25 | 1.95 ± 0.17 | 0.973 |
| Total cholesterol (mmol/L) | 6.77 ± 0.40 | 6.31 ± 0.39 | 0.399 |
| LDL cholesterol (mmol/L) | 3.81 ± 0.31 | 3.37 ± 0.42 | 0.385 |
| HDL cholesterol (mmol/L) | 2.06 ± 0.24 | 2.00 ± 0.18 | 0.834 |
Results are expressed as mean ± SEM. Abbreviations: BMI body mass index, TG triacylglycerol, HDL high-density lipoprotein, LDL low-density lipoprotein
Fig. 1Manhattan plot showing the |–log10(p)| -values (y-axis) of the Wilcoxon Mann Whitney U test, testing for metabolite differences in plasma between normal weight and obese pregnant women, stratified by lipoprotein species. Scattered line: uncorrected α-level at ±log10(0.05) = ±1.3
Fig. 2Score plot for the Principal Component Analysis of lipoprotein metabolite composition of normal weight and obese pregnant women
Top 10 plasma lipoprotein Metabolites with highest absolute loadings in principal component 1 (PrC1) and 2 (PrC2)
| Metabolite | PrC1 | Metabolite | PrC2 |
|---|---|---|---|
| SM C34:1 | 0.2633825 | PCae C38:5 | 0.24530123 |
| SM C36:1 | 0.23533697 | PCae C38:4 | 0.24105136 |
| SM C42:2 | 0.21961745 | PCae C40:6 | 0.2195198 |
| SM C41:1 | 0.215592 | PCae C42:6 | 0.21406066 |
| SM C34:2 | 0.20837699 | PCaa C44:12 | 0.20189903 |
| SM C42:3 | 0.20613141 | PCae C36:3 | 0.19888559 |
| PC C38:5 | −0.20204572 | PCaa C34:1 | −0.19755011 |
| SM C33:1 | 0.19581353 | PCae C36:4 | 0.1966289 |
| SM C32:1 | 0.1916571 | PCaa C32:1 | −0.19595342 |
| SM C33:3 | 0.19136632 | PCaa C34:2 | −0.19438766 |
Wilcoxon Mann Whitney U test showed significant differences in the SM to PC ratios between the lipoproteins with a significantly higher ratio of SM/PC in LDL compared to HDL and VLDL (Fig. 4)
Fig. 4Boxplot of the sphingomyelins (SM) to phosphatidylcholines (PC) ratios in LDL, VLDL and HDL. Significance based on Wilcoxon Mann Whitney U Test. ***: p-value < 0.001. HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein
Fig. 3Plot of the ratios between the metabolite medians and sum of all mono-unsaturated sphingomyelins (SM) as well as poly-unsaturated ester-linked phosphatidylcholines (PCaa) and ether-linked phosphatidylcholines (PCae) in the different lipoprotein species. The 95% confidence intervals for the ratios are estimated by bootstrapping and significance level calculated by Wilcoxon Mann Whitney U-Test. The definition of the stars is the following: ‘*’ P < 0.05, ‘**‘P < 0.01, ‘***’ P < 0.001 . Only metabolites that are significantly different in at least one comparison are included. HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein
Comparison of our findings of associations between single phospholipid species percentages and lipoproteins with those of Wiesner et al. 2009 (Bold font: same direction, normal font: different direction)
| Species | Wiesner et al. 2009 | Our analysis |
|---|---|---|
| polyunsaturated |
|
|
| saturated/monounsaturated |
|
|
| PCaa C32:0 | VLDL<LDL | VLDL>LDL |
|
|
| |
|
|
| |
| PCaa C36:4 |
|
|
|
|
| |
|
|
| |
| PCaa C38:5 |
|
|
|
|
| |
|
|
| |
| SM C32:1 | VLDL>LDL | VLDL<LDL |
|
|
| |
|
|
| |
| SM C33:1 | VLDL>LDL | VLDL<LDL |
|
|
| |
|
|
| |
| SM C34:2 | VLDL>LDL | VLDL<LDL |
|
|
| |
| LDL < HDL | LDL > LDL | |
| SM C34:1 | VLDL>LDL | VLDL<LDL |
| VLDL>HDL | VLDL<HDL | |
|
|
| |
| SM C35:1 | VLDL>LDL | VLDL<LDL |
|
|
| |
|
|
| |
| SM C36:2 | VLDL>LDL | VLDL<LDL |
|
|
| |
| LDL < HDL | LDL > HDL | |
| SM C36:1 |
|
|
| VLDL>HDL | VLDL<HDL | |
|
|
| |
| SM C41:2 |
|
|
|
|
| |
| LDL < HDL | LDL > HDL | |
| SM C41:1 |
|
|
|
|
| |
|
|
| |
| SM C42:3 | VLDL>LDL | VLDL<LDL |
|
|
| |
| LDL < HDL | LDL > HDL | |
| SM C42:2 |
|
|
|
|
| |
| LDL < HDL | LDL > HDL | |
| SM C42:1 |
|
|
|
|
| |
|
|
| |
| PCae C36:3 |
|
|
|
|
| |
|
|
| |
| PCae C38:5 |
|
|
|
|
| |
|
|
| |
| PCae C38:4 | VLDL>LDL | VLDL<LDL |
|
|
| |
|
|
| |
| PCae C40:6 | VLDL>LDL | VLDL<LDL |
| VLDL>HDL | VLDL<HDL | |
|
|
|